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Abstract Familial combined hyperlipidemia (FCHL) is a
common lipid disorder characterized by the presence of
multiple lipoprotein phenotypes that increase the risk of
premature coronary heart disease. In a previous study, we
identiWed an intragenic microsatellite marker within the
protocadherin 15 (PCDH15) gene to be associated with
high triglycerides (TGs) in Finnish dyslipidemic families.
In this study we analyzed all four known nonsynonymous
SNPs within PCDH15 in 1,268 individuals from Finnish
and Dutch multigenerational families with FCHL. Associa-
tion analyses of quantitative traits for SNPs were performed
using the QTDT test. The nonsynonymous SNP
rs10825269 resulted in a P = 0.0006 for the quantitative TG
trait. Additional evidence for association was observed with
the same SNP for apolipoprotein B levels (apo-B)
(P = 0.0001) and total cholesterol (TC) levels (P = 0.001).
None of the other three SNPs tested showed a signiWcant
association with any lipid-related trait. We investigated the
expression of PCDH15 in diVerent human tissues and
observed that PCDH15 is expressed in several tissues
including liver and pancreas. In addition, we measured the
plasma lipid levels in mice with loss-of-function mutations
in Pcdh15 (Pcdh15av-Tg and Pcdh15av-3J) to investigate pos-
sible abnormalities in their lipid proWle. We observed a sig-
niWcant diVerence in plasma TG and TC concentrations for
the Pcdh15av-3J carriers when compared with the wild type
(P = 0.013 and P = 0.044, respectively). Our study suggests
that PCDH15 is associated with lipid abnormalities.
Introduction
Familial combined hyperlipidemia (FCHL) is a complex
disease characterized by hypertriglyceridemia, hypercho-
lesterolemia or both (Goldstein et al. 1973). In addition,
high serum levels of apolipoprotein-B (apo-B) are often
observed in FCHL aVected individuals (Brunzell et al.
1983; Ayyobi et al. 2003). Several genome-wide scans
have been performed to detect susceptibility loci for FCHL
(Pajukanta et al. 1999; Aouizerat et al. 1999; Allayee et al.
2002). In a previous study, we identiWed an intragenic
microsatellite marker (D10S546) within the protocadherin
15 (PCDH15) to be associated with high serum triglycer-
ides (TGs) in Finnish dyslipidemic families (Lilja et al.
2004). Furthermore, PCDH15 resides in a region on chro-
mosome 10q11 that has been linked to lipid abnormalities
in several studies (Pajukanta et al. 1999; Lilja et al. 2004;
Huertas-Vazquez et al. 2005). PCDH15 is a member of the
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84 Hum Genet (2010) 127:83–89cadherin superfamily and encodes an integral membrane
protein that mediates calcium-dependent cell–cell adhesion.
Mutations in PCDH15 have been associated with hearing-
loss and visual-loss due to retinitis pigmentosa (Ahmed
et al. 2001; Alagramam et al. 2001a). Several previous epi-
demiological studies have demonstrated a relationship
between hearing loss and hyperlipidemia (Rosen et al.
1964; Rosen and Olin 1965; Evans et al. 2006; Chang et al.
2007). In this study, we investigated all known nonsynony-
mous SNPs within PCDH15, rs11004439, rs10825269,
rs4935502 rs2135720, for association with the FCHL com-
ponent traits, TGs, total cholesterol (TC) and apo-B in mul-
tigenerational Finnish and Dutch families with FCHL as
well as the PCDH15 expression pattern in diVerent human
tissues. In addition, we investigated the lipid proWle in mice
with two diVerent loss-of-function mutations in Pcdh15.
Subjects and methods
Finnish FCHL families
A total of 60 Finnish FCHL families comprising 719 indi-
viduals were included in this study. The families were
recruited in the Helsinki and Turku University Central Hos-
pitals. The inclusion and exclusion criteria for FCHL have
been described in detail previously (Pajukanta et al. 1999;
Soro et al. 2002). All subjects gave their informed consent.
The study design was approved by the ethics committees of
the participating centers.
Dutch FCHL families
A total of 32 Dutch FCHL families comprising 549 individuals
were included in this study. The families were recruited at
the Lipid Clinic of the Utrecht Academic University Hospital,
the Netherlands. The inclusion and exclusion criteria for
FCHL have been described in detail previously (Allayee
et al. 2002). All subjects provided written informed consent.
The study design was approved by the ethics committee of
the participating center.
Biochemical analysis and SNP genotyping
Serum lipid parameters were measured as described earlier
(Pajukanta et al. 1999; Soro et al. 2002; Allayee et al. 2002).
We selected all nonsynonymous SNPs within the PCDH15
gene, rs11004439, rs10825269, rs4935502 and rs2135720,
for genotyping. The SNP primers were designed for PCR
using the Primer3 program, and for detection, using the SNP
Primer Design software (Pyrosequencing). Genotyping of
the 1,268 Finnish and Dutch FCHL family members was
performed with the Pyrosequencing technique on the
automated PSQ HS96A platform. All SNPs had at least 92%
genotype call rate. For quality control, we replicated 3.5% of
the genotyped samples. The percentage agreement between
samples was >99%. All SNPs were tested for a possible vio-
lation of Hardy–Weinberg equilibrium (HWE).
Statistical analysis
All of the association analyses were performed using
quantitative lipid traits. The quantitative transmission
disequilibrium test (QTDT) (Abecasis et al. 2000) imple-
mented in the genetic analysis package SOLAR. QTDT
was performed for each analyzed trait in the Finnish and
Dutch families, both separately and in the combined data-
set. We analyzed the quantitative TG, TC, and apo-B, traits,
as they are the key component traits of FCHL. The residuals
for these traits were adjusted by age and sex in the total
sample, using the SPSS 12.0 program. The PedCheck pro-
gram was used to assess the genotype data for pedigree
inconsistencies (O’Connell and Weeks 1998). P values of
less than <0.05 after Bonferroni correction for multiple
testing were considered statistically signiWcant. However, it
is worth noting that the Bonferroni correction for the proba-
bility values obtained in these analyses can be considered
conservative, because we investigated highly correlated
lipid traits. Apo-A1 and HDL-C traits were analyzed as
secondary traits for rs10825269 after establishing the sig-
niWcant associations with TGs and apo-B.
To analyze whether rs10825269 aVects a combined trait
of HDL-C and TGs, we utilized option 19 of Mendel soft-
ware (Lange et al. 1976, 2001; Lange and Boehnke 1983).
Mendel option 19 performs QTL association using a vari-
ance components model. We used a bivariate model con-
sisting of an additive polygenic eVect, a random
environmental eVect, and an additive SNP regression
coeYcient. Standardized residuals for HDL and Log(TG)
were age and sex corrected, and proband ascertainment was
corrected for within Mendel. A likelihood ratio test was
performed using the formula: LRT = 2[ln(LH1) ¡ ln(LH2)],
where LH1 = maximum likelihood of the bivariate model,
and LH2 = maximum likelihood of the bivariate model with-
out the additive SNP regression coeYcient.
Simulation for functional change in coding nsSNPs
The PolyPhen software was used to investigate a possible
impact of all nonsynonymous changes on the structure and
function of the PCDH15 in silico.
Cross species comparisons
The cross species conservation of the nonsynonymous
SNPs was evaluated using the UCSC genome browser.123
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The expression of PCDH15 mRNA was analyzed using the
human multiple tissue cDNA panel 1 (Clontech). SpeciWc
primers for the PCR ampliWcation of PCDH15 were
5CCAGGACAAGCTATG TACTTCGAGTCCAAG-3
(forward) and 5-GACGAGTACATCGGCTTTGCCG
CTCAGTC-3 (reverse), amplifying a 396 bp fragment
(Rouget-Quermalet et al. 2006). AmpliWcation of speciWc
DNA fragments was performed by adding 3 l of cDNA
from the Human Tissue panel I to a PCR mixture contain-
ing 0.2 mM dNTPs, 0.4 M of each primer, 2 l of 10£
reaction buVer, 1.5 M MgCl2 and 0.2 l of Taq DNA
polymerase. PCR conditions were as follows: After initial
denaturation for 10 min at 94°C, the reaction was subjected
to 35 cycles of denaturation (30 s, 94°C), annealing (30 s,
61°C) and extension (1 min, 72°C). The ampliWed products
were separated on a 1% agarose gel electrophoresis.
G3PDH was used as a reference gene.
Animals
All the mice serum samples were collected at the Depart-
ment of Otolaryngology-Head and Neck Surgery, Case
Western Reserve University, University Hospitals-Case
Medical Center. All mice used in this study were main-
tained on regular mouse diet (6% fat IsoPro 3000 from
Purina that contains 6% fat).The mice were fasted for
12 h, beginning one hour after the start of their light
cycle. At the conclusion of the fast, the blood was col-
lected from each mouse using a retro-orbital bleed. A
total of 41 mice serums were collected for the FVB/N
genetic background Pcdh15av-Tg (n = 13 mutants: 3 males
and 10 females; and n = 8 controls: 4 males and 4
females), and for the C57BL/6J genetic background
Pcdh15av-3J (n = 9 mutants: 5 males, 4 females; and n = 11
controls: 4 males, 7 females). Mutant mice were generated
as described previously (Alagramam et al. 2001b). All
animal experimental protocols were approved by Institu-
tional Animal Care and Use Committee, Case Western
Reserve University.
Mice serum lipid measurement
All mice were fed a normal diet for 100 days and lipid con-
centrations were determined. TC and TGs were determined
as described previously (Castellani et al. 2004). Each lipid
determination was measured in triplicate. The statistical
analysis to evaluate diVerences in the mice lipid measure-
ments was determined by using the unpaired, two tailed
Student’s t test. Sex was included as a covariate in these
analyses. Values of P · 0.05 were considered to be
signiWcant.
Results
The mean lipid values of the 92 Dutch and Finnish FCHL
families included in this study are shown in Table 1. All
nonsynonymous SNPs within PCDH15 were genotyped in
these 92 Finnish and Dutch FCHL families. Genotype
distributions for the four investigated SNPs in both
populations were consistent with the Hardy–Weinberg
equilibrium in nonrelated groups of family members
(P > 0.05). Of the four nonsynonymous SNPs investigated,
SNP rs10825269 showed signiWcant evidence for associa-
tion for the diVerent quantitative lipid traits, TGs
(P = 0.001), apo-B (P = 0.002) and TC (P = 0.04) in the
Finns, and for the quantitative apo-B trait in the Dutch
(P = 0.04) for the same allele (C). No signiWcant associa-
tion signals were observed with the other three SNPs
rs11004439, rs4935502 and rs2135720 (P > 0.05). None of
the investigated SNPs were in linkage disequilibrium with
each other. Next we performed a combined data analysis of
both the Finnish and Dutch families with FCHL, and
observed a signiWcant increase of statistical signiWcance for
all investigated quantitative lipid traits (uncorrected
P = 0.001–0.0001, Bonferroni corrected P = 0.02–0.002).
Association results for the combined study sample for SNP
rs10825269 are presented in Table 2. We also investigated
the nonsynonymous SNP rs10825269 within PCDH15 for
associations with quantitative Apo-A1 and HDL-C levels in
the Finnish and Dutch FCHL families. No evidence for
association was observed for these traits (P > 0.05). The
frequency of the minor allele of the SNP rs10825269 in
both populations was 10%, which is in a good agreement
with the allele frequency reported by the International
HapMap project in the CEPH samples (http://www.
hapmap.org).
The chromosomal region on 10q11, where PCDH15 is
located, was also implicated for a combined trait of HDL-C
and TGs in our previous study (Lilja et al. 2004). There-
fore, we investigated whether rs10825269 aVects the com-
bined trait of HDL-C and TGs in the Dutch and Finnish
families with FCHL. For this analysis, we utilized option
Table 1 Mean lipid values of the 92 FCHL families included in the
study
M/F male/female, TG triglycerides, TC total cholesterol, Apo-B apoli-
poprotein-B, HDL-C HDL cholesterol
Finnish FCHL Dutch FCHL
No. of families 60 32
No. of subjects (M/F) 719 (356/363) 549 (273/276)
TG, mg/dl (mean § SD) 316.4 § 151.0 315.0 § 201.7
TC, mg/dl (mean § SD) 298.8 § 41.3 301.7 § 61.2
Apo-B, mg/dl (mean § SD) 146.7 § 31.1 141.8 § 24.6
HDL-C, mg/dl (mean § SD) 40.9 § 13.1 39.4 § 12.8123
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Boehnke 1983) (see Subjects and methods section). We
observed that rs10825269 does not signiWcantly alter this
combined trait (P = 0.08).
The nonsynonymous changes of rs10825269,
rs11004439 and rs2135720 were predicted to be benign by
the PolyPhen software (PSIC score diVerence: 0.057, 1.023
and 1.034, respectively). The SNP rs4935720, 166 bp away
from SNP rs10825269, was predicted to be possibly dam-
aging (PSIC score 1.7). We also examined the sequence
conservation across species of the nonsynonymous variants
within PCDH15. The cross-species conservations of these
nonsynonymous SNPs are shown in Fig. 1.
Next, we investigated the tissue distribution of PCDH15
in diVerent human tissues using a commercial human
multiple tissue cDNA panel of eight diVerent tissues. We
observed that PCDH15 was expressed in brain, heart, kid-
ney, liver, lung and pancreas. Figure 2 shows the expres-
sion patterns of PCDH15 in eight human adult tissues.
To investigate possible alterations in the lipid proWles of
the Pcdh15 mouse mutants, we measured the lipid levels of
two mouse mutants homozygous for diVerent loss of func-
tion mutation in Pcdh15 (Pcdh15av-Tg and Pcdh15av-3J)
(Fig. 3a). We observed a signiWcant decrease in plasma TG
and TC concentrations between the Pcdh15av-3J homozy-
gotes and age-match wild type siblings (P = 0.013 and
P = 0.044, respectively) (Fig. 3b). No statistically signiW-
cant diVerences were observed between the Pcdh15av-Tg
homozygotes and controls for any lipid trait (data not
shown).
Discussion
Results from our study suggest that the common allele of
SNP rs10825269 within PCDH15 is associated with TG,
apo-B and TC levels in FCHL. This SNP resides in the
same exon as the microsatellite D10S546 that was previ-
ously associated with high TGs in the Finnish families with
FCHL (Lilja et al. 2004). The functional role of the amino
acid substitution G380S in the lipid metabolism is
unknown. This amino acid substitution is located in the
extracellular domain and resides in a highly conserved resi-
due. Although the amino acid change was predicted to be
benign using the Polyphen software (Ramensky and Bork
2002), nonsynonymous SNPs in the coding region of a
gene could aVect the structure and function of the protein. It
Table 2 Quantitative family-based association analysis of lipid phe-
notypes with SNP rs10825269 in the Finnish and Dutch FCHL families
using the QTDT program
The risk allele is indicated in bold
TG triglycerides, TC total cholesterol, apo-B apolipoprotein-B
a Uncorrected P values (The Bonferroni correction for the probability
values obtained in these analyses can be considered conservative,
because we investigate highly correlated lipid traits)
b P values obtained after Bonferroni correction for 24 test (4 SNPs, 3






TG C/T 0.10 0.0006 0.01
Apo-B C/T 0.10 0.0001 0.002
TC C/T 0.10 0.001 0.02
Fig. 1 Nonsynonymous sequence variants in PCDH15. a All nonsyn-
onymous sequence variants within PCDH15. N-ter N-terminus of the
amino acid sequence, C1 cadherin domain 1, C2 cadherin domain 2,
etc.; C-ter C-terminus of the amino acid sequence. b Sequence conser-
vation across species of nonsynonymous variants in PCDH15. The
alignment includes Human (hs), chimpanzee (pt), rhesus monkey (rm),
mouse (mm), rat (rt), dog (cf), armadillo (dn), elephant (la), horse (ec).
S serine, A alanine, G glycine, D aspartic acid, R Arginine, Q Gluta-
mine, N aligning has one or more unalignable bases in the gap region
Variant hs pt rm mm rt cf dn la ec 
rs11004439 S S S S S A S N S 
rs10825269 G S S S S S S S S 
rs4935502 D D D D D D D D D 
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disequilibrium with another functional DNA variant at this
locus.
PCDH15 is a member of the cadherin superfamily of
calcium-dependent cell–cell adhesion molecules. PCDH15
plays an essential role in the maintenance of normal retinal
and cochlear function, and mutations in PCDH15 have
been associated with nonsyndromic (DFNB23) (Ahmed
et al. 2003) and syndromic hearing loss (the Usher syn-
drome type 1F, USH1F) (Ahmed et al. 2001; Alagramam
et al. 2001a). Although PCDH15 has not been directly
related with lipid abnormalities, previous biochemical
analysis suggested that USH1F patients have decreased
levels of long-chain polyunsaturated fatty acids in plasma
(Maude et al. 1998). In addition, previous epidemiological
studies have linked hearing loss to lipid abnormalities,
showing that hyperlipidemia and atherosclerosis can induce
alteration in cochlear function (Rosen et al. 1964; Rosen
and Olin 1965; Evans et al. 2006; Chang et al. 2007). The
biological role of protocadherins in lipid abnormalities is
unclear. The large size and diversity of members of the
protocadherin family suggest the participation of these
Fig. 2 Expression patterns of 
PCDH15 in eight human adult 
tissues (upper panel). G3PDH 



















































Fig. 3 a Mouse loss-of function mutations in Pcdh15 investigated in
this study. The solid rectangle indicates protein truncation due to pre-
mature stop mutations in the mutant mouse. N-ter N-terminus of the
amino acid sequence, C1 cadherin domain 1, C2 cadherin domain 2,
etc.; C-ter C-terminus of the amino acid sequence. b Levels of TGs and
total cholesterol in the Pcdh15 mouse mutant in the loss-of-function
allele Pcdh15av-3J, when compared to sibling controls. Groups of mice
were as follows: 9 mutant and 11 control mice (C57BL/6J genetic
background). TG and total cholesterol levels are expressed in mg/dl123
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studies of the Usher syndrome and visual abnormalities
have shown that PCDH15 is expressed in several tissues
including retina, brain, cerebellum, kidney, cochlea and
liver (Alagramam et al. 2001a; Rouget-Quermalet et al.
2006). In this study, the expression pattern of PCDH15 in
human was consistent with the pattern previously observed
in mice (Alagramam et al. 2001b; Rouget-Quermalet et al.
2006). Importantly, we also demonstrate that PCDH15
is expressed in human pancreas. Further investigation
is necessary to conWrm the role of PCDH15 in lipid abnor-
malities.
To the best of our knowledge, this is the Wrst time that
lipid traits have been investigated in the Pcdh15 mouse
mutant. Although additional studies are necessary to con-
Wrm our Wndings, these observations suggest a possible
alteration in the lipid proWle of the Pcdh15 mouse mutant
due to the Pcdh15av-3J loss-of-function mutation. No statis-
tically signiWcant diVerences were observed in the
Pcdh15av-Tg loss-of-function mutation. The observed results
suggest diVerences in the genetic background between the
FVB/N and C57BL/6J strains. This suggestion is indirectly
supported by a previous study demonstrating that the FVB/
N strain is susceptible to diet induce-atherosclerosis
whereas the C57BL/6J strain is resistant (Hoover-Plow
et al. 2006). A given phenotype could be obvious in one
inbred genetic background but it could be suppressed in
another genetic background (potential genetic modiWer
eVect; Nadeau 2001).
Genome-wide association analyses in unrelated
individuals have identiWed several loci associated with
lipid abnormalities. However, the variants identiWed so far
explain a small fraction of the disease risk, suggesting that
many genes implicated in the lipid metabolism still remain
undiscovered. We have previously identiWed several genes
associated with FCHL using family-based studies and
replicated our results in diVerent cohorts (Pajukanta et al.
2004; Huertas-Vazquez et al. 2005, 2008; Weissglas-Volkov
et al. 2006; Lee et al. 2008; Plaisier et al. 2009). Family-
based studies are more robust to population stratiWcation
and families ascertained for the disease of interest provide a
powerful tool for association studies.
In conclusion, we have identiWed a nonsynonymous var-
iant in PCDH15 associated with TG, apo-B and TC levels
in multigenerational Caucasian FCHL families. Replication
in additional FCHL study samples and sequencing of
PCDH15 are warranted to further explore the eVects of
PCDH15 in FCHL.
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